Clinical Trial Update: Ribociclib and Bicalutamide in AR+ TNBC [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 1/2 study of ribociclib in combination with bicalutamide for AR-positive triple-negative breast cancer, currently act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Ribociclib (ribociclib)
• bicalutamide (bicalutamide)

Snippet

Sponsor: Kari Wisinski | Conditions: Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING